These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
431 related articles for article (PubMed ID: 31645352)
1. Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. Friedman J; Moore EC; Zolkind P; Robbins Y; Clavijo PE; Sun L; Greene S; Morisada MV; Mydlarz WK; Schmitt N; Hodge JW; Schreiber H; Van Waes C; Uppaluri R; Allen C Clin Cancer Res; 2020 Feb; 26(3):679-689. PubMed ID: 31645352 [TBL] [Abstract][Full Text] [Related]
2. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Liu S; Knochelmann HM; Lomeli SH; Hong A; Richardson M; Yang Z; Lim RJ; Wang Y; Dumitras C; Krysan K; Timmers C; Romeo MJ; Krieg C; O'Quinn EC; Horton JD; Dubinett SM; Paulos CM; Neskey DM; Lo RS Cell Rep Med; 2021 Oct; 2(10):100411. PubMed ID: 34755131 [TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes. Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813 [TBL] [Abstract][Full Text] [Related]
4. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656 [TBL] [Abstract][Full Text] [Related]
5. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840 [TBL] [Abstract][Full Text] [Related]
6. Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma. Burrack AL; Spartz EJ; Raynor JF; Wang I; Olson M; Stromnes IM Cell Rep; 2019 Aug; 28(8):2140-2155.e6. PubMed ID: 31433988 [TBL] [Abstract][Full Text] [Related]
7. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467 [TBL] [Abstract][Full Text] [Related]
8. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy. Kumar A; Chamoto K; Chowdhury PS; Honjo T Elife; 2020 Mar; 9():. PubMed ID: 32122466 [TBL] [Abstract][Full Text] [Related]
9. PD-1/PD-L1 co-inhibition shapes anticancer T cell immunodominance: facing the consequences of an immunological ménage à trois. Haeryfar SMM; Schell TD Cancer Immunol Immunother; 2018 Nov; 67(11):1669-1672. PubMed ID: 30132082 [TBL] [Abstract][Full Text] [Related]
10. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709 [TBL] [Abstract][Full Text] [Related]
11. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720 [TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968 [TBL] [Abstract][Full Text] [Related]
13. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors. Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137 [No Abstract] [Full Text] [Related]
14. Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors. Nagaya T; Friedman J; Maruoka Y; Ogata F; Okuyama S; Clavijo PE; Choyke PL; Allen C; Kobayashi H Cancer Immunol Res; 2019 Mar; 7(3):401-413. PubMed ID: 30683733 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Oba T; Kajihara R; Yokoi T; Repasky EA; Ito F Cancer Res; 2021 Dec; 81(24):6183-6195. PubMed ID: 34666993 [TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Cloughesy TF; Mochizuki AY; Orpilla JR; Hugo W; Lee AH; Davidson TB; Wang AC; Ellingson BM; Rytlewski JA; Sanders CM; Kawaguchi ES; Du L; Li G; Yong WH; Gaffey SC; Cohen AL; Mellinghoff IK; Lee EQ; Reardon DA; O'Brien BJ; Butowski NA; Nghiemphu PL; Clarke JL; Arrillaga-Romany IC; Colman H; Kaley TJ; de Groot JF; Liau LM; Wen PY; Prins RM Nat Med; 2019 Mar; 25(3):477-486. PubMed ID: 30742122 [TBL] [Abstract][Full Text] [Related]
19. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. Guo Z; Wang H; Meng F; Li J; Zhang S J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551 [TBL] [Abstract][Full Text] [Related]
20. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma. Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]